¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active insufficiency"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • active marrow
    Ȱ¼º°ñ¼ö
  • active material
    Ȱ¼º¹°Áú, Ȱ¼ºÀç
  • active movement
    ´Éµ¿¿îµ¿
  • active negativism
    Àû±Ø°ÅºÎÁõ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active phase
    Ȱ¼º±â
  • active placebo
    Ȱ¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active negativism
    Àû±Ø°ÅºÎÁõ
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active placebo
    ¾ç¼º¼ÓÀÓ¾à
  • active prosthesis
    Ȱµ¿ÀÇÁö, ´Éµ¿ÀÇÁö
  • active shielding
    ´Éµ¿°¡¸², ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • active site
    Ȱ¼ººÎÀ§
  • active transport
    ´Éµ¿¿î¹Ý
  • active treatment
    Àû±ØÄ¡·á
  • active tuberculosis
    Ȱµ¿°áÇÙ
  • active gradient shielding
    ´Éµ¿±â¿ï±âÂ÷Æó, ´Éµ¿°æ»çÂ÷Æó
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ(Áõ)(üÀÔÑàõÌ¿ú·ñø).
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • hepatitis,chronic active
    ¸¸¼ºÈ°µ¿¼º(Ø·àõüÀÔÑàõ)
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • positive placebo =active p.
    ¾ç¼ºÇö󼼺¸, Ç¥Áؾà(øöñÞå·).
  • probe electrode =active e.
    Ž»öÀü±Ø.
  • Insufficiency, cardiac valve
    ½ÉÀåÆÇ¸·ºÎÀüÁõ(ãýíô÷ûدÜôîïñø)
  • accommodative insufficiency
    Á¶ÀýºÎÁ·
  • acute coronary insufficiency
    ±Þ¼º °üºÎÀü(¡­Î®ÝÕîï).
  • acute coronary insufficiency
    ±Þ¼º°ü»óµ¿¸ÆºÎÀü(¡­Î·ßÒÔÑØæÜôîï)
  • acute hepatic insufficiency
    ±Þ¼º °£ºÎÀü.
  • adrenal cortical insufficiency
    ºÎ½ÅÇÇÁú(±â´É)ºÎÀü(Áõ).
  • adrenal insufficiency
    ºÎ½Å(±â´É)ºÎÀü(¡­Ñ¦ÒöÝÕîï).
  • adrenal insufficiency
    ºÎ½Å(±â´É)ºÎÀü
  • adrenocortical insufficiency
    ºÎ½ÅÇÇÁúºÎÀüÁõ(Üùãìù«òõÝÕîïñø).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • assisted active exercise
    º¸Á¶´Éµ¿¿îµ¿.
  • assisted active exercise
    º¸Á¶´Éµ¿¿îµ¿.
  • cationic active agent
    ¾çÀÌ¿ÂȰ¼ºÁ¦(åÕ¡­üÀàõð¥).
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿¼º °£¿°(¡­ÊÜæú).
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • disinfectant, surface-active
    °è¸éȰ¼º¼Òµ¶Á¦
  • hepatitis,chronic active
    ¸¸¼ºÈ°µ¿¼º(Ø·àõüÀÔÑàõ)
  • immunity, active
    ´Éµ¿¸é¿ª
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • metabolically active stone
    ´ë»ç(¼º)Ȱ¼º(È­)°á¼®
  • positive placebo =active p.
    ¾ç¼ºÇö󼼺¸, Ç¥Áؾà(øöñÞå·).
  • probe electrode =active e.
    Ž»öÀü±Ø.
  • surface active disinfectant
    Ç¥¸éȰ¼º»ì±Õ¾à.
  • accommodative insufficiency
    Á¶ÀýºÎÁ·
  • acute coronary insufficiency
    ±Þ¼º °üºÎÀü(¡­Î®ÝÕîï).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • active phospholipid
    Ȱ¼ºÀÎÁöÁú (üÀàõ×òò·òõ)
  • active pyrophosphate
    Ȱ¼º(üÀàõ)ÇÇ·ÎÀλ꿰 (×òß«ç¤)
  • active pyruvate
    Ȱ¼º(üÀàõ)ÆÄÀÌ·çºê»ê¿° (ß«ç¤)
  • active site
    Ȱ¼º(üÀàõ)ÀÚ¸®
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • active sulfate
    Ȱ¼ºÈ²»ê¿° (üÀàõüÜß«ç¤)
  • active translocation
    Ȱ¼ºÀüÀ§ (üÀàõï®êÈ)
  • active transport
    ´Éµ¿¼ö¼Û (ÒöÔÑâÃáê)
  • flexible active site
    °¡º¯(ʦܨ) Ȱ¼º(üÀàõ)ÀÚ¸®
  • gradient-coupled active transport
    ±¸¹è(ÎþÛÕ) ¦Áø ´Éµ¿¼ö¼Û(ÒöÔÑâÃáê)
  • primary active transport
    ÀÏÂ÷ ´Éµ¿¼ö¼Û(ìéó­ÒöÔÑâÃáê)
  • secondary active transport
    ÀÌÂ÷ ´Éµ¿¼ö¼Û(ì£ó­ÒöÔÑâÃáê)
  • surface-active agent
    Ç¥¸éȰ¼ºÁ¦ (øúØüüÀàõð¥)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
UPI Utero-Placental Insufficiency
acc insuff accommodation insufficiency
AMVI acute mesenteric vascular insufficiency
BAI basilar artery insufficiency; beta-aminoisobutyrate
card insuff cardiac insufficiency
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PI Pancreatic insufficiency
RI Renal insufficiency
TI Tricuspid insufficiency
VPI Velopharyngeal insufficiency
VBI Vertebro basilar insufficiency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • active state
    Ȱµ¿ »óÅÂ
    ±ÙÀ°ÀÌ ¼öÃàÇÒ ¶§, ¼öÃà¿ä¼Ò ÀÚü¿¡ ÀϾ°í ÀÖ´Â ¿ªÇÐÀû »óÅÂÀÌ´Ù. ±ÙÀ° ÀÚü¿¡ ź¼º¿ä¼Ò°¡ Á¸ÀçÇϹǷΠ´Ü¼øÇÑ ¼öÃà°î¼±ÀÇ ±â·ÏÀ¸·Î Ȱµ¿»óȲÀ» ¾Ë ¼ö ¾ø´Ù. ¼öÃà¿ä¼Ò´Â ±ÙÀ°ÀÌ ÀڱصǸé Áï½Ã Ȱµ¿»óŰ¡ µÇ°í, Á¦2, Á¦3ÀÇ ÀÚ±ØÀÌ °¡ÇØÁ®µµ ÀÌ È°µ¿»óÅ´ °­È­µÇÁö ¾Ê°í ´Ü¼øÈ÷ Áö¼Ó½Ã°£ÀÌ ¿¬ÀåµÉ »ÓÀÌ´Ù.
  • active transport
    ´Éµ¿ À̵¿
    È®»ê¿¡ ÀÇÇØ¼­°¡ ¾Æ´Ï¶ó ¿î¹Ýü¿¡ ÀÇÇØ ¿¡³ÊÁö¸¦ ¼ÒºñÇØ °¡¸ç ³óµµ¿¡ ¿ªÇàÇØ¼­ ¹°ÁúÀÌ À̵¿µÇ´Â Çö»ó.
  • active tuberculosis
    Ȱµ¿¼º °áÇÙ, Ȱµ¿¼º °áÇÙÁõ
    ȯÀÚ¿¡¼­ ±ÕÀÌ °ËÃâµÇ´Â »óÅ¿¡ ÀÖ´Â °áÇÙ.
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • coagualtion-active substance
    ÀÀ°í Ȱ¼º ¹°Áú
  • full active opening
    ´Éµ¿ °³±¸·®
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • natural active immunity
    ÀÚ¿¬ ´Éµ¿ ¸é¿ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
pyloric insufficiency Patulousness of the pyloric outlet of the stomach, allowing regurgitation of duodenal contents into the stomach.
(05 Mar 2000)
divergence insufficiency That condition in which an exophoria or exotropia is more marked for near vision than for far vision.
(05 Mar 2000)
divergence insufficiency exotropia Exotropia in which the strabismus is notably greater for near vision than for far vision.
(05 Mar 2000)
insufficiency The condition of being insufficient or inadequate to the performance of the allotted duty.
Origin: L. Insufficientia, from sufficiens = sufficient
(18 Nov 1997)
thyroid insufficiency Subnormal secretion of hormones by the thyroid gland.
See: hypothyroidism.
(05 Mar 2000)
tricuspid insufficiency See: valvular insufficiency.
(05 Mar 2000)
tricuspid valve insufficiency Backflow of blood from the right ventricle into the right atrium, owing to imperfect functioning of the tricuspid valve.
(12 Dec 1998)
exocrine pancreatic insufficiency Lack of exocrine secretions of pancreas, due to destruction of acini, usually by chronic pancreatitis; lack of digestive enzymes from pancreas results in diarrhoea, usually fatty (steatorrhoea) because of lack of pancreatic enzymes.
(05 Mar 2000)
uterine insufficiency Atony of the uterine musculature.
(05 Mar 2000)
latent adrenocortical insufficiency Adrenocortical insufficiency not clinically evident but which can become severe if a sudden stress, such as an intercurrent acute illness, develops.
(05 Mar 2000)
active Characterised by action, not passive, not expectant.
(18 Nov 1997)
active acetate <enzyme> Condensation product of coenzyme A and acetic acid, symbolised as CoAS~COCH3; intermediate in transfer of two-carbon fragment, notably in its entrance into the tricarboxylic acid cycle and in fatty acid synthesis.
This coenzyme plays a huge role in intermediary metabolism, in which cells synthesise, break down or use nutrient molecules for energy production, growth, etc.
Acetyl-coenzyme A synthase is found in bacteria and plants and catalyses the reaction in which acetate enters metabolic pathways and forms acetyl-coenzyme A.
Synonym: acetyl-coenzyme A, active acetate.
(05 Mar 2000)
active aldehyde Any aldehyde derivative of thiamin pyrophosphate.
(05 Mar 2000)
active anaphylaxis Reaction following inoculation of antigen in a subject previously sensitised to the specific antigen, in contrast to passive anaphylaxis.
(05 Mar 2000)
active biomass <cell biology> The amount of a given culture that is actively growing.
(06 May 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á